An observational study in Dementia, sponsored by Northumbria Healthcare NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Northumbria Healthcare NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies in Dementia with a site in United Kingdom — 39 open to participants now, 58 under way, 12 of them phase 3. Dementia · United Kingdom.
Among the 178 studies in Dementia with a site in United Kingdom, this one is the 39th largest by planned enrollment of the 54 observational ones that give a count, is one of 6 that started in 2026, is one of 54 observational ones, reaches primary completion later than 21 of the 57 other live ones, and was the 174th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →39 of the 178 studies in Dementia with a site in United Kingdom are open now. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 55+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 55–90
Exciva GmbH · Sites in United Kingdom, United States, Canada and 6 more countries
Ages 55–90
University of Nottingham · Sites in United Kingdom
Ages 18–99 · Healthy volunteers
Prima Mente · Sites in United Kingdom
Ages 50+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 34 · Phase 3 40 · Phase 4 3
First in 1999; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 252 across 554 observational studies indexed under Dementia.
Median enrollment 196 across the 124 interventional studies, 210 across the 54 observational. Of the 94 that completed or were terminated, 27 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 178 have an industry lead sponsor. The 10 most frequent:
Northumbria Healthcare NHS Foundation Trust is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Northumbria Healthcare NHS Foundation Trust has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
9 of the studies in Dementia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07347431Northumbria Healthcare NHS Foundation TrustLarge Language Model for Understanding and Monitoring Elderly Neurocognition | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT06263920Lancashire Teaching Hospitals NHS Foundation TrustNeurofrailty: A Study of Late-onset Epilepsy and Its Associations | 2027-01-12 |
| NCT06937541University of West LondonFamily Interventions iN Dementia Mental Health Environments | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 178 studies in Dementia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. However, these histories can be incomplete, unstructured, or difficult to obtain, making diagnosis more challenging.
This study will test LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition), an AI-powered conversation tool designed to help caregivers describe their loved one's symptoms more effectively. By asking structured questions and guiding the conversation, LUMEN can create clear, well-organised reports for memory clinic doctors. This could make assessments quicker, more accurate, and less stressful for families.
We will test LUMEN in real-world clinics by asking caregivers and doctors to use it and provide feedback. We want to understand how easy it is to use, whether it could improve the quality of information shared, and how it fits into existing NHS memory clinic processes. We will also run co-production workshops with community groups to ensure the tool is accessible to people from diverse cultural and language backgrounds.
This research is exciting because it explores how artificial intelligence can improve dementia care. If successful, LUMEN could enhance the diagnostic process, reduce carer burden, and help more people access dementia support sooner. In the future, this tool could be used nationwide in memory clinics, improving care for thousands of families.
Background and Rationale Dementia diagnosis relies on clinical history, cognitive assessments, and collateral information from caregivers. However, obtaining structured and reliable collateral histories is challenging due to caregiver burden, recall bias, and time constraints in memory clinics. Large language models (LLMs) have the potential to improve this process by guiding structured history-taking, extracting clinically relevant details, and standardising information gathering.
LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition) is an AI-powered conversational tool designed to assist caregivers in providing structured collateral histories before clinical dementia assessments. Seed-funded by the Royal College of Psychiatrists, the Alzheimer's Research UK Northern Network and the Newcastle Biomedical Research Network, LUMEN was developed to enhance diagnostic accuracy, reduce caregiver burden, and improve workflow efficiency in memory clinics.
This study will evaluate the feasibility, usability, and acceptability of LUMEN in real-world clinical settings through a nested qualitative feasibility study. We will recruit caregivers and clinicians to interact with LUMEN and assess its effectiveness in gathering collateral histories. The study will also incorporate co-production workshops with community groups to explore issues around language, cultural inclusivity, and accessibility. Findings will inform future refinements and a larger validation study.
This study aims to:
3. Background Work Undertaken LUMEN was co-developed with clinicians and stakeholders using a Modified Delphi process involving 150 clinicians, primarily old age psychiatrists. This produced 2,600 questions mapped to validated dementia tools, ensuring clinical relevance. Early technical testing evaluated open-source LLMs (e.g., Mistral 7B, LLaMA2 7B) using simulated clinical vignettes. ROC curve analysis demonstrated an AUC of 0.89 for distinguishing dementia-related narratives, and Cohen's Kappa 0.82 indicated high inter-rater reliability between LUMEN's outputs and clinician ratings. Early PPIE (Patient and Public Involvement and Engagement) feedback highlighted the need for simpler language, cultural sensitivity, and improved user experience. These insights will be further refined through the proposed co-production workshops.
4. Study Design and Methodology This study will employ a mixed-methods approach, combining quantitative usability testing with qualitative interviews to evaluate LUMEN's feasibility and acceptability.
4.1. Participants and Recruitment
4.2. Study Procedures
Baseline Data Collection:
LUMEN Interaction:
Usability and Cognitive Load Assessment:
Qualitative Evaluation:
Exploratory Analysis:
5. Milestones and Timescales
The study will run for 12 months (April 2025 - April 2026), with key phases as follows:
Phase Month Activities Preparation \& Ethics 1-3 Final IRAS approval, NHS R\&D approvals, team setup Recruitment \& Data Collection 4-9 Patient-carer dyad recruitment, clinician recruitment, LUMEN testing Usability Workshops 6-8 Co-production workshops, qualitative interviews Data Analysis \& Refinement 9-10 Thematic analysis, SUS/NASA-TLX scoring, LLM refinements Final Reporting \& Next Steps 11-12 Dissemination, grant preparation for large-scale validation study 6. Expected Impact This study will generate critical feasibility data to inform a larger clinical validation study and subsequent NHS integration. Expected outcomes include:
Patient and carer dyads: patients attending the Memory Clinic for assessment of cognitive problems.
Clinicians: specialist doctors or advanced nurse practitioners responsible for dementia diagnosis
Carers of patients attending Memory Clinic appointments; Aged 18 or over; Both patients and cares can provide ; Basic English literacy
Clinicians must have at least 2 years of specialist dementia care experience and be personally responsible for dementia diagnosis; Must be provide informed consent
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent. • Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment. 1. Baseline Data Collection: * Demographics (age, gender, ethnicity, socioeconomic status). * Clinical diagnosis (where available). * Cognitive test scores (MoCA/ACE). 2. LUMEN Interaction: o Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (\~20-30 min). 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=10 carers).
Other: LUMEN prototype software interaction
4.1. Participants and Recruitment • Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience. 4.2. Study Procedures 1. Baseline Data Collection: o Demographics (age, gender, ethnicity, socioeconomic status). 2. LUMEN Interaction: o Clinicians will review LUMEN-generated histories to assess completeness and clinical utility. 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=4-5 clinicians).
Other: LUMEN prototype software interaction
This is a prototype software which seeks to gather collateral information relevant to a dementia clinical assessment.
SUS (System Usability Scale)
10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
Time frame: Immediately after use of software
NASA-TLX (Task Load Index):
Evaluates perceived cognitive workload (scores 0-29 = low workload).
Time frame: Immediately after prototype interaction
Thematic analysis
Qualitative analysis of dialogues from semi-structured interviews
Time frame: 1-10 days after use of prototype software
Plan to share: Undecided — This will include personal narratives of participants' dementia journeys which may contain sensitive information
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 9 months is below that.
Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northumbria Healthcare NHS Foundation Trust